Koers Peregrine Pharmaceuticals Nasdaq
Aandelen
US7136613046
Farmaceutische producten
Omzet 2024 * | 139 mln. 129 mln. | Omzet 2025 * | 164 mln. 152 mln. | Marktkapitalisatie | 524 mln. 487 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -20 mln. -18,59 mln. | Nettowinst (verlies) 2025 * | -11 mln. -10,22 mln. | EV/omzet 2024 * | 3,77 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,19 x |
K/w-verhouding 2024 * |
-26
x | K/w-verhouding 2025 * |
-44
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,9% |
Recentste transcriptie over Peregrine Pharmaceuticals
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Nicholas Green
CEO | Chief Executive Officer | 60 | 30-07-20 |
Daniel Hart
DFI | Director of Finance/CFO | 50 | 01-08-18 |
Nick Ferguson
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-99 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gregory Sargen
BRD | Director/Board Member | 59 | 27-11-17 |
Joseph Carleone
CHM | Chairman | 78 | 27-11-17 |
Catherine Mackey
BRD | Director/Board Member | 68 | 25-07-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,79% | 88,14 mld. | |
+1,45% | 40,51 mld. | |
-15,94% | 31,67 mld. | |
+52,66% | 24,62 mld. | |
-14,50% | 15,65 mld. | |
-14,38% | 12,07 mld. | |
-9,12% | 11,97 mld. | |
-42,56% | 11,61 mld. | |
+4,87% | 8,81 mld. |